Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775994 | 0.77 | L3MBTL1 (0.39) | L3MBTL1HCRTR1HCRTR2HTR4AURKA | |
| SCHEMBL24995375 | 0.77 | L3MBTL1 (0.42) | L3MBTL1HCRTR1HCRTR2HTR4AURKA | |
| SCHEMBL29297543 | 0.77 | TNKS (0.33) | L3MBTL1HCRTR1HCRTR2HTR4 | |
| SCHEMBL2179459 | 0.77 | L3MBTL1 (0.41) | L3MBTL1HCRTR2ROCK1AURKA | |
| SCHEMBL26937867 | 0.76 | NUDT1 (0.50) | L3MBTL1HCRTR1HCRTR2AURKA | |
| Bromide SCHEMBL17873904 | 0.75 | L3MBTL1 (0.40) | L3MBTL1ROCK1AURKA | |
| SCHEMBL27114743 | 0.73 | TNKS (0.36) | L3MBTL1HCRTR1HCRTR2HTR4 | |
| SCHEMBL21376993 | 0.73 | L3MBTL1 (0.36) | L3MBTL1HCRTR1HCRTR2HTR4 | |
| SCHEMBL17321402 | 0.73 | ROCK1 (0.43) | L3MBTL1PTGER1ROCK1AURKA | |
| SCHEMBL2871017 | 0.72 | PDE10A (0.34) | L3MBTL1ROCK1AURKAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-12-27 | — | — | US | disclosed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016101119-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106106-A2 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-30 | — | — | WO | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | PDE12, PDE10A, PDE5A | L3MBTL1 4459/4885HCRTR1 1852/4885HCRTR2 2185/4885 |
| US-20180370973-A1 | FUSED HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | L3MBTL1 4347/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.